What Are the Most Common Bromocriptine Side Effects?

The functional indication of bromocriptine mesylate is spontaneous, tumorous, and drug-induced amenorrhea after childbirth. Prolactin-induced menstrual disorders, infertility and secondary amenorrhea reduce ovulation. Inhibits lactation and prevents lactation after childbirth and premature delivery. Postpartum breast congestion, special breast tenderness, breast tenderness, and irritability caused by prolactin. Low androgen caused by prolactin, such as infertility caused by impotence and reduced sperm. Adjuvant treatment of acromegaly. Anti-tremor paralysis: This product is effective and long-lasting.

Bromocriptine mesylate

This entry lacks an overview map . Supplementing related content makes the entry more complete and can be upgraded quickly. Come on!

The functional indication of bromocriptine mesylate is spontaneous, tumorous, and drug-induced amenorrhea after childbirth. Prolactin-induced menstrual disorders, infertility and secondary amenorrhea reduce ovulation. Inhibits lactation and prevents lactation after childbirth and premature delivery. Postpartum breast congestion, special breast tenderness, breast tenderness, and irritability caused by prolactin. Low androgen caused by prolactin, such as infertility caused by impotence and reduced sperm. Adjuvant treatment of acromegaly. Anti-tremor paralysis: This product is effective and long-lasting.

Chinese name

Bromocriptine mesylate

Whether medical insurance medication

Non-medical insurance

Whether over-the-counter

prescription

Specifications

Tablets: 2.5mg each.

The main ingredients:

Traits: tablets.

Amenorrhea caused by croup or prolactin, menstrual disease and low fertility, at the beginning, 0.125mg once a day, 2 or 3 times a day, if the dose is indeed insufficient, it can be gradually increased to 0.25mg once a day, 2 3 times, take after meals. Continue treatment until lactation stops. For amenorrhea, functional menstrual disease, and low fertility, treatment should continue until menstruation returns to normal. If necessary, treatment can be continued for several cycles to prevent recurrence. Inhibition of lactation: 0.25mg once, twice a day, morning and evening with food, continuous medication for 14 days. Should be taken after childbirth. After stopping the drug, occasionally a small amount of milk is secreted for 2 to 3 days, and it can be stopped after taking the same dose for several days. Breast hyperemia after childbirth: Those who are mild can take 0.25 mg orally once, and can repeat once every 12 hours if lactation is not required. Low androgen caused by prolactin: 5 to 10 mg per day. Acromegaly: 2.5mg a day, after 7 to 14 days, it can gradually increase to 10-20mg according to the clinical response, divided into 4 servings with food. Tremor palsy: Start with 1.25mg each time, twice a day, and gradually increase the dose within 2 weeks, and increase 2.5mg daily from 14-28 days to find the minimum dose with the best effect.

And note that if combined with levodopa can improve the efficacy, but the application of 10mg of this product needs to reduce the dose of levodopa by 12.5%. The main adverse reactions are nausea, headache, dizziness, fatigue, abdominal pain, vomiting, etc. Hypotension, ADHD, dyskinesia, and mental symptoms can also occur. The incidence of adverse reactions was about 68%. It can be relieved after continuous medication, and it can be relieved when taken with food. About 3% need to discontinue medication.

Drug Name: Bromocriptine Mesylate

Drug aliases: bromocriptine, bromocriptine, bromocriptine Parlodel

English name: Bromocriptine Mesilate

Drug Description: No

Main ingredients: No

Traits: No

Indications: Polypeptide ergot alkaloids, selective fluid dopamine receptors, and D2 receptors excite tremor paralysis and anti-tremor paralysis at normal doses. The curative effect is better than that of amantadine and benzoline for rigidity and less Good dynamic effect, good effect on critically ill patients. This product is also a prolactin inhibitor, used to prevent and stop physiological lactation and accompanying amenorrhea or anovulation. Tremor paralysis that is ineffective or insensitive to levodopa treatment. It can also be used for amenorrhea caused by various reasons after delivery; inhibit lactation; breast swelling caused by oxytocin.

Dosage: Oral tremor and paralysis, starting at 1.25mg / times, 2 times / day, and then increasing by 1.25mg 2.5mg every 2 weeks or every month until it takes effect. Usually 10mg 20mg / day. It is used for amenorrhea, menstrual diseases and low fertility. For inhibiting lactation: 0.25mg once, twice a day, and even for 14 days.

Adverse reactions: No

Note: Pregnancy class C. Patients with severe psychiatric history and myocardial infarction are contraindicated. Patients with peripheral vascular disease and peptic ulcer should be used with caution.

Because bromocriptine has dopaminergic activity, it can effectively treat Parkinson's disease when used at higher doses than the endocrine indications. Bromocriptine stimulates dopamine receptors and restores dopamine deficiency in specific nigrostriatal matter that causes Parkinson's disease. Clinically, bromocriptine improves tremor, stiffness, sluggish movements, and other symptoms at any stage of Parkinson's disease. Usually the effect can be maintained for many years (so far, patients have maintained good results for 8 years). Bromocriptine can be used alone in the early and late stages, or it can be combined with other anti-Parkinson's disease drugs. Combination with levodopa can strengthen the anti-Parkinson's disease effect, and can reduce the amount of levodopa. Bromocriptine can be particularly effective in patients who have experienced a long-term use of levodopa with reduced efficacy or abnormal involuntary movements (such as chorea-like dyskinesia and / or painful dystonia), end-of-treatment failure and "switching" the treatment. Bromocriptine can improve the depression commonly seen in patients with Parkinson's disease, which is due to the antidepressant effect unique to bromocriptine. This effect was confirmed in controlled trials in patients with non-Parkinson's disease with endogenous or psychotic depression.

[Indications] Irregular menstruation and infertility caused by too high prolactin (prolactin is too high or normal), such as amenorrhea (milk or no milk), the luteal phase is too short, some psychotherapeutics or anti- Hyperprolactinemia caused by hypertension drugs. Infertility that is not related to prolactin, such as polycystic ovary syndrome, anovulation cycle (in combination with antiestrogens, such as clomiphene). [Chemical composition] [Pharmacological action] Because bromocriptine has dopaminergic activity, it can effectively treat Parkinson's disease when used at higher doses than the endocrine indications. Bromocriptine stimulates dopamine receptors and restores dopamine deficiency in specific nigrostriatal matter that causes Parkinson's disease. Clinically, bromocriptine improves tremor, stiffness, sluggish movements, and other symptoms at any stage of Parkinson's disease. Usually the effect can be maintained for many years (so far, patients have maintained good results for 8 years). Bromocriptine can be used alone in the early and late stages, or it can be combined with other anti-Parkinson's disease drugs. Combination with levodopa can strengthen the anti-Parkinson's disease effect, and can reduce the amount of levodopa. Bromocriptine can be particularly effective in patients who have experienced long-term use of levodopa or have involuntary movements (such as chorea-like dyskinesia and / or painful dystonia), end-of-treatment failure, and "switching". the treatment. Bromocriptine can improve the depression commonly seen in patients with Parkinson's disease, which is due to the antidepressant effect unique to bromocriptine. This effect was confirmed in controlled trials in patients with non-Parkinson's disease with endogenous or psychotic depression.

[Drug interactions] Bromocriptine is metabolized by the cytochrome P450 (CYP3A) enzyme system. And macrolide antibiotics (such as: erythromycin, clarin, aceandomycin, spiramycin, josamycin), azole antifungals (such as ketoconazole, itraconazole ) Or a combination of cytochrome P450 enzyme inhibitors (such as cimetidine) can increase the blood concentration of bromocriptine, leading to an increased risk of adverse reactions. It has been reported that combination with octreotide can increase the blood concentration of bromocriptine, thereby increasing the risk of adverse reactions. Therefore, octreotide should be avoided. Combination with methyl ergometrine or other ergot alkaloids may increase the risk of adverse reactions, so they should be avoided. Alcohol reduces the tolerance of bromocriptine.

[Adverse reactions] In the first few days of treatment, some patients may experience nausea, and very few patients may experience dizziness, fatigue, vomiting, or diarrhea, but not so severe that they need to be discontinued. Bromocriptine can cause orthostatic hypotension, and individual patients may collapse, so patients should monitor their blood pressure, especially during the first few days of treatment. Such symptoms can be treated symptomatically. The following adverse reactions have also been reported: nasal congestion, constipation, drowsiness, headache, a few patients occasionally have mental disorders, psychomotor excitement, hallucinations, dyskinesia, dry mouth, lower limb spasm, intramuscular pain, skin allergic reactions and hair loss. Most of these side effects are dose-related and usually can be controlled by reducing the dose.

There have been reports of a few patients with sensory disturbances, peripheral arterial disturbances (such as slight ischemia of the limbs), and reversible paleness of the fingers and toes caused by cold during long-term treatment, especially in patients with Raynaud's disease. Occasionally, arterial spasm and gangrene have been reported. Aggravated angina, bradycardia, and transient arrhythmia (branch branch block) have been reported after using bromocriptine. In a few cases, hypertension, myocardial infarction, seizures, strokes, and mental disorders occur when bromocriptine is used to suppress postpartum lactation. It has been documented that patients with long-term treatment (several years) and daily doses of 30 mg or more experience retroperitoneal and pleural fibrosis, but only for patients receiving bromocriptine for Parkinson's disease.

[Contraindications] Those who are allergic to any of the ingredients of this product or other ergotine. Control unsatisfactory hypertension, pregnancy (including eclampsia, preeclampsia and hypertension during pregnancy), postpartum and postpartum hypertension. Coronary heart disease and other serious cardiovascular diseases. Patients with symptoms and / or history of severe mental disorders. Patients with cerebrovascular accident, arterial obstructive disease, Raynaud's sign, and history of nicotine addiction.